vha-15 Antibody

What is vha-15 and why is it important in C. elegans research?

Vha-15 is a subunit of the vacuolar H⁺-ATPase (v-ATPase) complex in C. elegans, a multi-subunit protein assembly responsible for acidifying various cellular compartments. This 54.2 kDa protein (UniProt ID: Q22494) is essential for many cellular processes including:

• Endosomal/lysosomal acidification

• Membrane trafficking and polarity maintenance

• Longevity regulation

• Mitochondrial stress response pathways

Research interest in vha-15 has increased due to findings that some v-ATPase subunits, when knocked down by RNAi, extend lifespan by ~60% in C. elegans, activating what has been termed the Lysosomal Surveillance Response (LySR) . Unlike some v-ATPase subunits that reduce lifespan when targeted (e.g., vha-1, vha-4, vha-16, vha-19), vha-15 RNAi has been shown to extend lifespan, making it a compelling target for aging research .

What types of vha-15 antibodies are available for C. elegans research?

Currently, the primary type of antibody available for vha-15 research is polyclonal antibodies raised in rabbits. Based on commercial and published information, these antibodies typically:

• Are raised against specific epitopes of the C. elegans vha-15 protein

• Are supplied in liquid format with preservatives (e.g., 0.03% Proclin 300) and stabilizers (50% Glycerol in PBS, pH 7.4)

• Have been validated for applications including ELISA and Western blotting

Researchers should note that antibody options for C. elegans research are more limited compared to mammalian models, requiring careful validation in your specific experimental context.

How should I store and handle vha-15 antibodies to maintain their activity?

Proper storage and handling of vha-15 antibodies are critical for maintaining their activity:

• Store at 4°C for short-term use (1-2 weeks)

• Store at -20°C for long-term storage and future applications

• Avoid repeated freeze-thaw cycles; consider aliquoting antibodies upon receipt

• If received on dry ice, centrifuge the vial briefly to collect any liquid entrapped in the cap

• When diluting, use clean buffers (PBS with 0.1% BSA or similar carrier protein) to prevent non-specific binding

Unlike some antibodies, vha-15 antibodies may not require special reconstitution if supplied in glycerol-containing buffer, but always check the specific product documentation.

How can I validate a vha-15 antibody for my specific application?

Antibody validation is essential for ensuring reliable results, especially when working with C. elegans proteins:

• Positive control verification: Use wild-type C. elegans lysate alongside a vha-15 overexpression construct if available.

• Negative control testing: Include lysate from vha-15 RNAi-treated worms. The band intensity should be significantly reduced but may not be eliminated.

• Specificity assessment: Use Western blotting to confirm a single band at 54 kDa.

• Cross-reactivity testing: Assess whether the antibody recognizes other v-ATPase subunits by comparing to purified recombinant proteins if available.

• RNAi knockdown validation: Similar to approaches used for other v-ATPase antibodies, researchers have validated antibody specificity by comparing protein levels in control versus RNAi conditions (as seen with other v-ATPase subunits like vha-6) .

What are the optimal conditions for using vha-15 antibodies in Western blotting?

Based on methodologies used for other C. elegans v-ATPase subunits:

• Sample preparation:

  • Harvest and wash worms in M9 buffer

  • Lyse using a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and protease inhibitors

  • Sonicate briefly and centrifuge to clear debris

• Electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal resolution of the 54 kDa vha-15 protein

  • Transfer to PVDF or nitrocellulose membrane at 100V for 1 hour or 30V overnight at 4°C

• Blocking and antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Incubate with primary vha-15 antibody (1:500-1:1000 dilution) overnight at 4°C

  • Wash with TBST (3×10 minutes)

  • Incubate with appropriate HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

  • Develop using ECL reagent

These conditions may require optimization based on your specific antibody and sample type.

How can I design experiments to study vha-15 interaction with other proteins in the v-ATPase complex?

To study protein-protein interactions involving vha-15:

• Co-immunoprecipitation (Co-IP):

  • Use vha-15 antibody coupled to protein A/G beads to precipitate vha-15 and associated proteins

  • Analyze precipitated complexes by Western blotting with antibodies against other v-ATPase subunits

  • Consider crosslinking approaches for transient interactions

• Proximity labeling:

  • Generate transgenic C. elegans expressing vha-15 fused to BioID or TurboID

  • After biotin labeling, purify biotinylated proteins and identify by mass spectrometry

  • Validate interactions with Co-IP or other methods

• Fluorescence resonance energy transfer (FRET):

  • Create fluorescently-tagged vha-15 and potential interaction partners

  • Perform FRET measurements in live worms to detect interactions in situ

  • Control experiments with non-interacting proteins are essential

These approaches can reveal the dynamics of vha-15 assembly into the v-ATPase complex and identify novel interaction partners.

How does vha-15 antibody transfection technique compare with traditional immunostaining for studying intracellular interactions?

Antibody transfection presents a unique approach for studying intracellular protein interactions:

When applied to vha-15 research, antibody transfection could potentially:

• Reveal dynamic interactions between vha-15 and other v-ATPase components

• Monitor vha-15 trafficking and localization in response to cellular stressors

• Assess functional consequences of antibody binding to vha-15 in living cells

This technique has been successfully applied to study disease-related antibody:protein interactions in neurons and could be adapted for vha-15 studies .

What are the considerations for using vha-15 antibodies in immuno-electron microscopy?

Immuno-electron microscopy (immuno-EM) provides ultrastructural localization of vha-15:

• Sample preparation options:

  • For ultrathin cryosections: Fix worms with 4% paraformaldehyde plus 0.1% glutaraldehyde in M9 buffer

  • Embed in 12% gelatin and infuse in 2.3M sucrose

  • Process for ultracryomicrotomy with 80nm sections

• Immunogold labeling protocol:

  • Apply primary vha-15 antibody (typically 1:50-1:100 dilution)

  • Detect using protein A conjugated to gold particles (e.g., 10nm PAG)

  • For co-localization studies, use different sized gold particles for each target

• Control experiments:

  • Include sections without primary antibody

  • Use pre-immune serum as negative control

  • Validate specificity with vha-15 RNAi-treated worms

This approach would allow precise localization of vha-15 at the ultrastructural level, potentially revealing its distribution within specific membrane microdomains or subcellular compartments.

What are common issues with vha-15 antibody applications and how to resolve them?

For vha-15 specifically, researchers should note that its expression can be affected by environmental stressors, so experimental conditions should be carefully controlled and reported.

How can I distinguish between specific and non-specific binding when using vha-15 antibodies?

To confirm antibody specificity:

• Peptide competition assay:

  • Pre-incubate the antibody with excess peptide antigen

  • Apply to duplicate samples in parallel with non-blocked antibody

  • Specific signals should be substantially reduced in the peptide-blocked samples

• Genetic controls:

  • Compare wild-type samples with vha-15 knockdown or knockout samples

  • True specific signals should be significantly reduced in knockdown/knockout samples

• Multiple antibody validation:

  • If available, use multiple antibodies recognizing different epitopes of vha-15

  • Specific signals should be detected by all antibodies

• Signal pattern analysis:

  • Specific binding should show consistent subcellular localization patterns

  • Non-specific signals often appear diffuse or variable between samples

These approaches help ensure that observed signals truly represent vha-15 localization and not artifacts.

How can vha-15 antibodies be used to study the role of V-ATPase in longevity and stress response pathways?

Vha-15 antibodies can provide insights into longevity mechanisms:

• Protein level changes during aging:

  • Compare vha-15 protein levels in wild-type worms at different ages

  • Correlate changes with lifespan and healthspan phenotypes

  • Identify post-translational modifications using specialized antibodies

• Subcellular redistribution under stress:

  • Use immunofluorescence to track vha-15 localization during stress responses

  • Correlate with activation of stress response pathways like LySR

• Interaction with longevity regulators:

  • Perform co-IP with vha-15 antibodies in long-lived mutants (e.g., daf-2)

  • Identify changes in v-ATPase complex composition or interactions

• Pathway interaction studies:

  • Combine vha-15 antibody studies with genetic or pharmacological manipulation of longevity pathways

  • For example, examine how vha-15 protein levels or localization change in response to TORC1 inhibition, as the v-ATPase/TORC1-mediated ATFS-1 translation has been shown to direct mitochondrial stress responses

These approaches can reveal how vha-15 contributes to the extended lifespan observed in certain v-ATPase RNAi conditions.

Can vha-15 antibodies be modified for therapeutic or diagnostic applications?

While primarily research tools, vha-15 antibodies could potentially be engineered for expanded applications:

• Antibody engineering options:

  • Single-chain variable fragments (scFvs): These ~25 kDa fragments retain antigen-binding capacity while providing better tissue penetration

  • Bispecific antibodies: Combining vha-15 binding with another target could enable targeted manipulation of v-ATPase function

  • Nanobodies: Using camelid VHH domains could provide high-affinity, stable alternative to conventional antibodies

• Potential diagnostic applications:

  • Monitoring v-ATPase complex integrity as a biomarker for certain conditions

  • Development of quantitative assays for lysosomal dysfunction

• Research tool applications:

  • Intracellular antibody delivery to manipulate vha-15 function in living cells

  • This approach has been successfully applied to study neuronal dysfunction in diseases like multiple sclerosis

These advanced applications would require extensive validation and optimization beyond standard research antibody applications.

How do experimental findings with vha-15 antibodies compare to studies using genetic manipulation of vha-15?

Understanding the relationship between antibody-based and genetic studies is crucial:

Researchers have demonstrated that vha-15 RNAi impacts lifespan , but protein-level studies using antibodies could reveal whether this effect correlates with reduced protein levels or altered protein localization/interactions, providing mechanistic insights impossible with genetic approaches alone.

How can vha-15 antibody research inform studies of V-ATPase in human disease?

V-ATPase dysfunction has been implicated in various human diseases, and C. elegans vha-15 research may provide valuable insights:

• Comparative analysis:

  • Vha-15 is homologous to human ATP6V0C

  • Antibody studies in C. elegans can reveal conserved functions and regulations

  • Findings from worm studies can guide hypothesis generation for human disease research

• Disease models:

  • Many neurodegenerative diseases involve lysosomal dysfunction

  • Vha-15 antibody studies in C. elegans models of these diseases could reveal mechanisms of pathogenesis

  • For example, antibody studies could determine if v-ATPase mislocalization contributes to disease phenotypes

• Therapeutic target validation:

  • If vha-15 manipulation extends lifespan in C. elegans, understanding the underlying molecular mechanisms could identify conserved targets for human therapeutic development

  • Antibody studies provide protein-level insights that complement genetic approaches

This translational potential highlights the broader impact of basic research using vha-15 antibodies.

How should researchers interpret contradictory results between vha-15 antibody studies and transcriptomic data?

When facing contradictions between protein and mRNA data:

• Technical considerations:

  • Antibody specificity issues may cause misleading protein quantification

  • RNA extraction or sequencing biases may affect transcriptomic results

  • Sample timing differences may capture different regulatory events

• Biological explanations:

  • Post-transcriptional regulation may cause protein levels to diverge from mRNA levels

  • Protein stability differences can result in protein accumulation despite low transcript levels

  • Feedback mechanisms may counterregulate protein vs. mRNA

• Resolution strategies:

  • Use multiple antibodies targeting different epitopes

  • Validate with orthogonal methods (mass spectrometry)

  • Perform time-course studies to capture dynamic regulation

  • Consider cell/tissue heterogeneity in whole-organism studies

For example, if transcriptomic studies show increased vha-15 mRNA after stress but antibodies detect decreased protein, this could reflect active protein degradation or translational inhibition rather than a technical artifact.